一种用于艰难梭菌分离培养的新型显色培养基的性能评价

目的评价自主研发的艰难梭菌显色培养基(CDCA)性能。方法选用艰难梭菌及其他细菌的标准株进行CDCA显色的特异性评价;将艰难梭菌标准菌株梯度稀释后测定BD公司CDSA、生物梅里埃公司CDIF和CDCA的灵敏度。收集临床120份粪便样本分别采用3种培养基进行艰难梭菌分离培养,并对生长菌落进行质谱鉴定和tpi基因检测,以3种平板中任1种能培养出艰难梭菌的样本定义为真阳性。结果在CDCA平板上除了梭形梭菌、双酶梭菌、第三梭菌、脆弱拟杆菌等菌种能够少量生长并显色外,对其他实验菌种均有抑制作用。CDSA、CDIF和CDCA检测艰难梭菌的灵敏度分别为2.0×10~5 CFU/mL、8.0×10~1 CFU/mL和4.0×10~2 CFU/mL。120份标本中检出艰难梭菌31份(25.8%),CDSA、CDIF和CDCA培养阳性标本分别为25份(20.8%)、28份(23.3%)和26份(21.7%),3种显色培养基对临床腹泻标本检测阳性率差异无统计学意义(χ~2=0.418,P=0.811)。3种显色培养基的敏感性、特异性、阳性预测值、阴性预测值分别为:CDCA 83.8%、100%、100%、94.7%;CDIF 90.3%、98.9%、96.6%、96.7%;CDSA 80.6%、100%、100%、93.7%。结论本实验室研发的CDCA的特异性和灵敏度较高,可用于临床艰难梭菌的初步分离。     

Clinical management of severe,fulminant, and refractory Clostridioides difficile infection

ABSTRACT

Introduction: Up to 15% of hospitalized patients with Clostridioides difficile infection (CDI) develop severe CDI (SCDI) or Fulminant CDI (FCDI). Due to high rates of mortality in medically-refractory CDI cases, 30% of patients with severe infection historically require surgical intervention. However, colectomy itself is an imperfect solution because it is difficult to predict who will fail medical therapy, patients with SCDI are more likely to have underlying medical conditions that make them poor surgical candidates, and post-surgical mortality still approaches 30–50%.

Areas covered: This review will serve as a clinically-based review of severe and fulminant CDI management including discussion of models to predict severe infection, emerging treatments, novel targets for therapy, and innovations in surgical management.

Expert opinion: Among the most promising studies to emerge in the last decade have involved fecal microbiota transplantation (FMT), which is already recommended by multiple society guidelines for recurrent CDI (RCDI). In the case of SCDI/FCDI, multiple studies have safely and successfully utilized FMT to produce rates of cure in the 70–90% range. Additionally, patients who have FCDI refractory to medical therapy and are poor candidates for colectomy may benefit from FMT as salvage therapy.     

Xpert艰难梭菌检测系统的临床应用评价

目的评估Xpert艰难梭菌检测系统的临床应用价值。方法选取43份腹泻粪便标本,采用厌氧培养法、VIDAS检测A/B毒素法和Xpert艰难梭菌检测系统检测艰难梭菌,以产毒培养法作为金标准对检测方法进行评价,并比较不同检测方法对临床标本检测结果的一致性。通过自配027型标准菌株模拟粪便标本,验证Xpert艰难梭菌检测系统筛选027型流行株的能力。结果以产毒培养法为金标准,Xpert艰难梭菌检测系统的敏感性和特异性分别为90.9%和93.8%,阳性和阴性预测值分别为83.3%和96.8%。与产毒培养法结果一致性检验Kappa值为0.822(P0.05),与VIDAS检测A/B毒素法结果一致性检验Kappa值为0.419(P0.05);027型标准菌株模拟粪便标本检测结果阳性并报告为027型。结论 Xpert艰难梭菌检测系统能够快速准确地检测粪便标本中的艰难梭菌相关基因,且能准确报告027型高产毒力菌株。     

Extubation difficile imprévue

Complications at extubation remain an important risk factor in anaesthesia. Airway related complications at extubation are relatively frequent but are usually dealt with by simple basic measures. We report a new case of respiratory complications associated with tracheal extubation in a 59-year-old woman. Her medical history included obesity, no criteria difficult intubation and no adverse events during her previous anesthetic procedures. At the end of surgery, immediately after extubation, the patient developed respiratory distress requiring reintubation. A second extubation performed in postoperative recovery room was complicated by a new respiratory distress with reintubation. The patient was then admitted to the ICU. The examination on admission was unremarkable. Chest X-ray and a chest CT scan were performed in search of an etiology. Both tests showed a large thyroid “goitre plongeant” (plunging goiter) and compressive. In the suites, a thyroidectomy was performed with excision of a large cervical plunging goiter para- and retropharyngeal bilateral chest, allowing extubation successfully. The postoperative course was uneventful.     

Intubation au vidéolaryngoscope sous-sédation

We report a video laryngoscopic tracheal intubation under sedation in a patient with a hip fracture. Preoperative assessment revealed signs of difficult airway management linked to a cervical spine immobilization. Here we describe an alternative method to awake fiber optic flexible intubation.     

Comparaison de l’Airtraq™ et du laryngoscope Macintosh pour l’intubation trachéale chez l’adulte avec stabilisation manuelle en ligne du rachis cervical

Introduction

Airtraq laryngoscope is a new and single use device for endotracheal intubation. Few studies showed the superiority of the Airtraq comparing to Macintosh laryngoscope in the setting of difficult intubation.

Study design

To compare the performance of these two laryngoscopes by simulating a situation of reduced mobility of the cervical spine by applying the Manual in-line stablization (MILS) maneuver.

Patients and methods

After obtaining the approval of the ethic committee, we realized a prospective single blind randomized study. During a 6-month period, 120 consenting patients scheduled for ORL or ophthalmologic surgery were included. They all had general anesthesia and orotracheal intubation. These patients were randomly and equally divided in two groups (n = 60), depending on the type of the laryngoscope used (Airtraq or Macintosh). Were excluded from the study the patients with history or criteria predicting difficult intubation. Each patient was intubated by one of the five experimented anesthetists selected for this work. The principle judgment criteria were: i) the time taken for the orotracheal intubation and ii) the intubation difficulty score (IDS). The secondary judgment criterion was the hemodynamic modifications after the endotracheal intubation.

Results

Demographic and upper airway track variables were comparable between the two groups. There was no case of failure of intubation in this serie. Nonetheless, all the patients of the Airtaq group were intubated from the first attempt, whereas half of the patients of the Macintosh group were intubated after the third attempt. Comparing to the Macintosh, the Airtraq reduces the time taken for the orotracheal intubation (14 ± 1 s vs 19 ± 3 s, P = 0.01), the necessity of additional maneuver to facilitate the intubation, and the intubation difficulty score (0.7 ± 0.3 vs 3.8 ± 1, P < 0.001). Orotracheal intubation using the Airtraq laryngoscope caused less hemodynamic stimulation than using the Macintosh.

Conclusion

Our study showed the usefulness of the Airtraq laryngoscope for endotracheal intubation for patients presenting conditions of difficult intubation such as reduced mobility of the cervical spine.     

The epidemiology of Clostridium difficile infection in patients with cancer

Introduction: Clostridium difficile infection (CDI) is a significant cause of healthcare-associated diarrhoea, and the emergence of endemic strains resulting in poorer outcomes is recognised worldwide. Patients with cancer are a specific high-risk group for development of infection.

Areas covered: In this review, modifiable and non-modifiable risk factors for CDI in adult patients with haematological malignancy or solid tumours are evaluated. In particular, the contribution of antimicrobial exposure, hospitalisation and gastric acid suppression to risk of CDI are discussed. Recent advances in CDI treatment are outlined, namely faecal microbiota transplantation and fidaxomicin therapy for severe/refractory infection in cancer populations. Outcomes of CDI, including mortality are presented, together with the need for valid severity rating tools customised for cancer populations.

Expert commentary: Future areas for research include the prognostic value of C. difficile colonisation in cancer patients and the potential impact of dedicated antimicrobial stewardship programs in reducing the burden of CDI in cancer units.     

Successful treatment of fulminant Clostridioides difficile infection with emergent fecal microbiota transplantation in a patient with acute myeloid leukemia and prolonged,severe neutropenia

We present a patient with acute myeloid leukemia and prolonged, severe neutropenia who developed fulminant Clostridioides difficile infection refractory to medical therapy and was high‐risk for surgical intervention. He was treated with fecal microbiota transplantation (FMT) for life‐saving cure. The patient had subsequent clinical improvement, however, developed multidrug‐resistant Pseudomonas aeruginosa bacteremia 2 days post‐procedure. We describe subsequent investigation of this event that found this bacteremia was not related to the donor stool administered during FMT. This case adds to the literature that FMT could be considered in heavily immunocompromised patients with fulminant Clostridioides difficile infection where maximal medical therapy has been ineffective and surgery may carry an excessively high mortality risk.     

抗艰难梭菌rakicidin B1新衍生物的设计、合成及生物学活性评价

目的 以rakicidin B1为起始原料,经2步反应合成得到4个全新结构的rakicidin B1衍生物,并对其进行生物学活性研究,以期获得低细胞毒、高效抗艰难梭菌活性的化合物。方法 课题组前期首次发现rakicidin B1具有较强的抗艰难梭菌活性,在其结构基础上进行修饰和优化,通过氨基甲酸酯连接基团引入含氮杂环,设计合成得到4个全新目标化合物。所有化合物结构经高分辩质谱和核磁确证,并经抗艰难梭菌活性测试和细胞毒性活性测试。结果 在合成的4个化合物中,有3个化合物具有与先导化合物更强或相当的抗艰难梭菌活性;同时,MTT测试结果表明,3个化合物的细胞毒性降低,以3b的细胞毒性降低最多。结论 通过对rakicidin B1母核结构进行修饰和优化,获得全新结构的rakicidin B1衍生物并对其进行抗菌和细胞毒活性筛选。其中,化合物3b保留潜在抗艰难梭菌活性且细胞毒性降低最多,作为全新结构类型的抗艰难梭菌活性化合物,有潜在的开发价值。